{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:24:48Z","timestamp":1791822288226,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["2018-06047"],"award-info":[{"award-number":["2018-06047"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41429-019-0186-8","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T12:03:39Z","timestamp":1556280219000},"page":"605-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli"],"prefix":"10.1038","volume":"72","author":[{"given":"Ronald","family":"Domalaon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreofe","family":"Okunnu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"186_CR1","doi-asserted-by":"publisher","first-page":"12872","DOI":"10.1073\/pnas.1717162115","volume":"115","author":"EJ Klemm","year":"2018","unstructured":"Klemm EJ, Wong VK, Dougan G. Emergence of dominant multidrug-resistant bacterial clades: lessons from history and whole-genome sequencing. Proc Natl Acad Sci USA. 2018;115:12872\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"186_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-018-0634-9","volume":"20","author":"KL Schwartz","year":"2018","unstructured":"Schwartz KL, Morris SK. Travel and the spread of drug-resistant bacteria. Curr Infect Dis Rep. 2018;20:29.","journal-title":"Curr Infect Dis Rep"},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.chest.2018.06.019","volume":"154","author":"AK Guitor","year":"2018","unstructured":"Guitor AK, Wright GD. Antimicrobial resistance and respiratory infections. Chest. 2018;154:1202\u201312.","journal-title":"Chest"},{"key":"186_CR4","doi-asserted-by":"crossref","unstructured":"Domalaon R, Idowu T, Zhanel GG, Schweizer F. Antibiotic hybrids: the next generation of agents and adjuvants against Gram-negative pathogens? Clin Microbiol Rev. 2018;31:pii:e00077\u201317.","DOI":"10.1128\/CMR.00077-17"},{"issue":"3","key":"186_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ijantimicag.2018.10.011","volume":"53","author":"Despoina Koulenti","year":"2019","unstructured":"Koulenti D et al. Infections by multidrug-resistant Gram-negative bacteria: what\u2019s new in our arsenal and what\u2019s in the pipeline? Int J Antimicrob Agents. 2018;53:211\u2013224. \n                    https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.011","journal-title":"International Journal of Antimicrobial Agents"},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s15010-016-0905-z","volume":"45","author":"Z Liu","year":"2017","unstructured":"Liu Z, et al. In vitro and in vivo activity of EDTA and antibacterial agents against the biofilm of mucoid Pseudomonas aeruginosa. Infection. 2017;45:23\u201331.","journal-title":"Infection"},{"issue":"3","key":"186_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00726-018-2673-9","volume":"51","author":"Ronald Domalaon","year":"2018","unstructured":"Domalaon R et al. Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria. Amino Acids. 2018;51:383\u2013393. \n                    https:\/\/doi.org\/10.1007\/s00726-018-2673-9","journal-title":"Amino Acids"},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2174\/1568026615666150915112459","volume":"16","author":"R Domalaon","year":"2016","unstructured":"Domalaon R, Zhanel GG, Schweizer F. Short antimicrobial peptides and peptide scaffolds as promising antibacterial agents. Curr Top Med Chem. 2016;16:1217\u201330.","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"186_CR9","doi-asserted-by":"publisher","first-page":"e02374","DOI":"10.1128\/AAC.02374-17","volume":"62","author":"Ronald Domalaon","year":"2018","unstructured":"Domalaon R et al. Short proline-rich lipopeptide potentiates minocycline and rifampin against multidrug- and extensively drug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018;62:pii:e02374-17.","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2217\/fmb-2016-0021","volume":"11","author":"S Das","year":"2016","unstructured":"Das S, Dasgupta A, Chopra S. Drug repurposing: a new front in the war against Staphylococcus aureus. Future Microbiol. 2016;11:1091\u20139.","journal-title":"Future Microbiol"},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1128\/AAC.00192-16","volume":"60","author":"E Hennessy","year":"2016","unstructured":"Hennessy E, Adams C, Reen FJ, O\u2019Gara F. Is there potential for repurposing statins as novel antimicrobials? Antimicrob Agents Chemother. 2016;60:5111\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"186_CR12","doi-asserted-by":"publisher","first-page":"e0124595","DOI":"10.1371\/journal.pone.0124595","volume":"10","author":"R Rajamuthiah","year":"2015","unstructured":"Rajamuthiah R, et al. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS ONE. 2015;10:e0124595.","journal-title":"PLoS One"},{"key":"186_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ijantimicag.2018.02.003","volume":"51","author":"H Mohammad","year":"2018","unstructured":"Mohammad H, AbdelKhalek A, Abutaleb NS, Seleem MN. Repurposing niclosamide for intestinal decolonization of vancomycin-resistant Enterococci. Int J Antimicrob Agents. 2018;51:897\u2013904.","journal-title":"Int J Antimicrob Agents"},{"key":"186_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22037-x","volume":"8","author":"N Tharmalingam","year":"2018","unstructured":"Tharmalingam N, Port J, Castillo D, Mylonakis E. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. Sci Rep. 2018;8:3701.","journal-title":"Sci Rep"},{"key":"186_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07705-w","volume":"9","author":"J Tam","year":"2018","unstructured":"Tam J, et al. Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota. Nat Commun. 2018;9:5233.","journal-title":"Nat Commun"},{"key":"186_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep33642","volume":"6","author":"M Gooyit","year":"2016","unstructured":"Gooyit M, Janda KD. Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile. Sci Rep. 2016;6:33642.","journal-title":"Sci Rep"},{"key":"186_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","volume":"41","author":"W Chen","year":"2018","unstructured":"Chen W, Mook RAJ, Premont RT, Wang J. Niclosamide: beyond an antihelminthic drug. Cell Signal. 2018;41:89\u201396.","journal-title":"Cell Signal"},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1128\/AAC.01952-12","volume":"57","author":"F Imperi","year":"2013","unstructured":"Imperi F, et al. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob Agents Chemother. 2013;57:996\u20131005.","journal-title":"Antimicrob Agents Chemother"},{"key":"186_CR19","doi-asserted-by":"crossref","unstructured":"Domalaon R, De Silva PM, Kumar A, Zhanel GG, Schweizer F. The anthelmintic drug niclosamide synergizes with colistin and reverses colistin resistance in Gram-negative bacilli. Antimicrob Agents Chemother. In press, manuscript accepted (AAC02574-18R1). 2019;63:pii:02574-18.","DOI":"10.1128\/AAC.02574-18"},{"key":"186_CR20","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1021\/acs.molpharmaceut.5b00098","volume":"12","author":"G Costabile","year":"2015","unstructured":"Costabile G, et al. Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: development of inhalable formulations through nanosuspension technology. Mol Pharm. 2015;12:2604\u201317.","journal-title":"Mol Pharm"},{"key":"186_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/phar.1537","volume":"35","author":"PJ Bergen","year":"2015","unstructured":"Bergen PJ, et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy. 2015;35:34\u201342.","journal-title":"Pharmacotherapy"},{"key":"186_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","volume":"16","author":"YY Liu","year":"2016","unstructured":"Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161\u20138.","journal-title":"Lancet Infect Dis"},{"key":"186_CR23","doi-asserted-by":"publisher","first-page":"e89189","DOI":"10.1371\/journal.pone.0089189","volume":"9","author":"R Rajamuthiah","year":"2014","unstructured":"Rajamuthiah R, et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS ONE. 2014;9:e89189.","journal-title":"PLoS One"},{"key":"186_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.bioorg.2018.07.018","volume":"80","author":"R Domalaon","year":"2018","unstructured":"Domalaon R, Berry L, Tays Q, Zhanel GG, Schweizer F. Development of dilipid polymyxins: investigation on the effect of hydrophobicity through its fatty acyl component. Bioorg Chem. 2018;80:639\u201348.","journal-title":"Bioorg Chem"},{"key":"186_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijantimicag.2007.10.005","volume":"31","author":"AZ Sahalan","year":"2008","unstructured":"Sahalan AZ, Dixon RA. Role of the cell envelope in the antibacterial activities of polymyxin B and polymyxin B nonapeptide against Escherichia coli. Int J Antimicrob Agents. 2008;31:224\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"186_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nrmicro1994","volume":"6","author":"JM Pages","year":"2008","unstructured":"Pages J-M, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol. 2008;6:893\u2013903.","journal-title":"Nat Rev Microbiol"},{"key":"186_CR27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/femsre\/fux020","volume":"41","author":"S Chevalier","year":"2017","unstructured":"Chevalier S, et al. Structure, function and regulation of Pseudomonas aeruginosa porins. FEMS Microbiol Rev. 2017;41:698\u2013722.","journal-title":"FEMS Microbiol Rev"},{"key":"186_CR28","doi-asserted-by":"publisher","first-page":"E641","DOI":"10.9778\/cmajo.20160080","volume":"4","author":"A Walkty","year":"2016","unstructured":"Walkty A, et al. Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008\u20132015). CMAJ Open. 2016;4:E641\u2013E645.","journal-title":"CMAJ Open"},{"key":"186_CR29","unstructured":"The Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing CLSI supplement M100S. 26th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016."},{"key":"186_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/ja.2015.127","volume":"69","author":"TB Tran","year":"2016","unstructured":"Tran TB, et al. Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii. J Antibiot. 2016;69:415\u201321.","journal-title":"J Antibiot"},{"key":"186_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2885.1987.tb00089.x","volume":"10","author":"NA Mohammed-Ali","year":"1987","unstructured":"Mohammed-Ali NA, Bogan JA. The pharmacodynamics of the flukicidal salicylanilides, rafoxanide, closantel and oxyclosanide. J Vet Pharmacol Ther. 1987;10:127\u201333.","journal-title":"J Vet Pharmacol Ther"},{"issue":"Suppl 1","key":"186_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jac\/dkt022","volume":"68","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007\u201311 study. J Antimicrob Chemother. 2013;68(Suppl 1):7\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"186_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acsinfecdis.7b00145","volume":"3","author":"R Domalaon","year":"2017","unstructured":"Domalaon R, Yang X, Lyu Y, Zhanel GG, Schweizer F. Polymyxin B3-tobramycin hybrids with Pseudomonas aeruginosa-selective antibacterial activity and strong potentiation of rifampicin, minocycline, and vancomycin. ACS Infect Dis. 2017;3:941\u201354.","journal-title":"ACS Infect Dis"},{"key":"186_CR34","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1021\/acs.jmedchem.6b01742","volume":"60","author":"Y Lyu","year":"2017","unstructured":"Lyu Y, et al. Amphiphilic tobramycin-lysine conjugates sensitize multidrug resistant Gram-negative bacteria to rifampicin and minocycline. J Med Chem. 2017;60:3684\u2013702.","journal-title":"J Med Chem"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0186-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:32:02Z","timestamp":1684618322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-019-0186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1038\/s41429-019-0186-8","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}